The concept of targeted cytotoxic drug delivery to reduce systemic toxicity while increasing treatment efficacy was first introduced by Paul Ehrlich in 1913. However, it was only a century later that this concept turned into reality when the first antibody-drug conjugate (ADC) gained regulatory approval.

ADCs continue to demonstrate efficacy across different tumor types, and their use is expected to expand across indications as more suitable target antigens are identified and new and better technologies emerge.

In this article, we explore the market growth of ADCs, innovations in the ADC space, and the future of ADCs as a targeted therapy for various diseases, including cancer.

Global CRO/CDMO Syngene offers a highly integrated ‘one-stop-shop’ approach for ADCs underpinned by strong conceptual frameworks, experimental design, and cutting-edge technology. Our end-to-end capabilities range from pharmacokinetics and toxicology to discovery-grade conjugation and characterization, Linker payload synthesis (cytotoxic and non-cytotoxic) and optimization, and antibody discovery and engineering. All our ADC services are available as standalone and integrated services across antibody discovery, bioconjugation, bioassay, and ADC chemistry